By screening a library of compounds for the ability to induce mitotic defects, researchers have identified AZ0108 as a potent PARP6 inhibitor, which exerts antitumor effects in vivo and induces cell death in breast cancer cells in vitro (Wang et al., 2018). This evidence concerns the gene PARP6 and breast carcinoma.